Dirlotapide is a gut-selective inhibitor of microsomal triglyceride transfer protein (MTP). It reliably produces weight loss in obese dogs.

Dogs receiving dirlotapide (0.3 mg/kg) once daily have a small but significant decrease (6.16 ± 2.22%) in crude fat digestibility compared with the placebo-treated food-restricted dogs, but no difference in crude protein, dry matter, or energy digestibility is observed. Dirlotapide effectively reduces appetite and energy intake without affecting nutrient digestibility, except for a minimal decrease in fat digestibility [1]. Dirlotapide (0.5 mg/kg) results in a high rate of weight loss (3.3% weekly) and anorexia, emesis, and loose stools for some dogs. Dirlotapide produces weight loss by both reducing appetites (about 90% of the weight loss activity) and by increasing fecal fat excretion (about 10% of the weight loss activity) [2].

481658-94-0

C40H33F3N4O3

674.71

CP742033;Slentrol;Dirlotapide

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years